Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Depreciation & Amortization (CF) (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $31000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation & Amortization (CF) fell 41.51% year-over-year to $31000.0, compared with a TTM value of $193000.0 through Dec 2024, down 1.53%, and an annual FY2024 reading of $193000.0, down 1.53% over the prior year.
  • Depreciation & Amortization (CF) was $31000.0 for Q4 2024 at Oramed Pharmaceuticals, down from $52000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $56000.0 in Q1 2024 and bottomed at $11000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 3 years is $37250.0, with a median of $44500.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 260.0% in 2023, then plummeted 41.51% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $17000.0 in 2022, then skyrocketed by 211.76% to $53000.0 in 2023, then tumbled by 41.51% to $31000.0 in 2024.
  • Business Quant data shows Depreciation & Amortization (CF) for ORMP at $31000.0 in Q4 2024, $52000.0 in Q3 2024, and $54000.0 in Q2 2024.